The reactivity of Oxone towards 4,6-di(cycloamino)-1,3-phenylenediamines : synthesis of spirocyclic oxetane ring-fused imidazobenzimidazoles by Conboy, Darren & Al-Dabbagh, Fawaz




The Free Internet Journal 




 Arkivoc 2020, part vii, 180-191 
 
The reactivity of Oxone towards 4,6-di(cycloamino)-1,3-phenylenediamines: 
synthesis of spirocyclic oxetane ring-fused imidazobenzimidazoles  
 
Darren Conboy and Fawaz Aldabbagh 
 
Department of Pharmacy, School of Life Sciences, Pharmacy and Chemistry, Kingston University, Penrhyn Road, 
Kingston upon Thames, KT1 2EE, U.K. 
Email: f.aldabbagh@kingston.ac.uk  
 
Dedicated to Professor Jan Bergman on the occasion of his 80th birthday 
Received   04-25-2020 Accepted   06-29-2020 Published on line   07-31-2020 
 
Abstract 
Spirocyclic oxetane ring-fused imidazo[4,5-f]benzimidazole and imidazo[5,4-f]benzimidazole are reported. 
Oxone-mediated ring-closures to give imidazobenzimidazoles require acid and the functionalization of the 4,6-
di(cycloamino)-1,3-phenylenediamine to the anilides. This is in contrast to benzimidazole forming oxidative 
cyclizations, which use 2-(cycloamino)anilines and require no acid. New evidence for N-oxide and nitroso-
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Introduction 
 
Imidazobenzimidazoles exist in a [4,5-f] and [5,4-f] arrangement and are scaffolds at the core of antitumor 
agents.1–5 A valuable strategy for the discovery of chemotherapeutics is the targeting of proteins over-
expressed in solid tumors, such as NAD(P)H:quinone oxidoreductase 1 (NQO1, also known as DT-diaphorase).6 
For iminoquinone derivatives of imidazo[5,4-f]benzimidazoles, a hydrogen bonding acceptor improves binding 
at the NQO1 active site.5  Oxetane is a robust hydrogen bonding alternative to carbonyl functionalities and a 
polar analogue of the gem-dimethyl group.7,8 Spirocyclic oxetane 1 was fused onto benzimidazole via oxidative 
cyclizations of 2-(2-oxa-7-azaspiro[3.5]nonan-7-yl)aniline 2a and acetamide analogue 2b using H2O2 with HI 
and Oxone (potassium peroxymonosulfate) in formic acid to give 3a and 3b respectively (Scheme 1).9,10 In this 
article, our synthetic targets are spirocyclic oxetane ring-fused isomers, imidazo[4,5-f]benzimidazole 4 and 








Figure 1.  Target imidazobenzimidazoles and the investigated diamine. 
 
The fundamental advantage of using the Oxone protocol over earlier reported radical cyclization 
methods,3 is the ability to synthesize imidazobenzimidazoles (e.g. 7) containing two different fused rings 
(Scheme 2).4 For cyclization, acid has to be present, and m-CPBA in acetone gave the diamine N-oxide 8, as the 
sole product. Treatment of diamine-N-oxide 8 with formic acid in the absence of an external oxidant gave ring-
fused benzimidazole 9, and a mechanism for oxidative cyclization through the internal conjugated system of 8 
was provided.4 The use of Oxone for the preparation of these fanciful imidazobenzimidazole scaffolds is 
reminiscent of early work by Spiegel and Kaufmann, who utilized Caro’s acid (peroxysulfuric acid) to cyclize 5-
nitro-2-(piperidin-1-yl)aniline to give benzimidazole.11 Our group has also shown that H2O2 can be utilized in 
the absence of acid for some cyclizations of 2-(cycloamino)anilines,12 and with HX (X = Cl and Br) to give 
selectively halogenated ring-fused benzimidazoles,13 and benzimidazolequinones.14 In this article, we examine 
the reactivity of Oxone towards anilide derivatives of 4,6-di(piperidin-1-yl)-1,3-phenylenediamine (6) (Figure 
1), as part of studies towards the preparation of spirocyclic oxetane ring-fused imidazobenzimidazoles 4 and 5.  
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Scheme 2.  Reported oxidative cyclizations and evidence of diamine N-oxide intermediate. 4 
 
 
Results and Discussion 
 
Treating diamine 6 with Oxone in acid did not give imidazo[4,5-f]benzimidazole, but led to intractable 
mixtures. This is in line with our findings in Scheme 2,4 where decreasing the electron-density by acetylating at 
the primary amines of 6 was necessary. This led us to investigate the effect of Oxone on the mono-anilide 
derivative of 6. Slow addition of sterically hindered pivaloyl chloride was necessary in order to minimize 
reaction at both amines of 6, which gave the desired N-[5-amino-2,4-di(piperidin-1-yl)phenyl]-2,2-
dimethylpropanamide (10) and N,N'-[4,6-di(piperidin-1-yl)-1,3-phenylene]bis(2,2-dimethylpropanamide) (11) 




Scheme 3.  Functionalizing 4,6-di(piperidin-1-yl)-1,3-phenylenediamine (6) with pivaloyl chloride. 
 
Reaction of amine-anilide 10 with Oxone in a 10% aqueous solution of hexafluoroisopropanol (HFIP) gave 
the intriguing adduct 12 in 58% yield, resulting from cyclization and N-oxide formation at the amine and 
anilide parts respectively (Scheme 4). Mono-cyclized adduct 13 was also formed in 29% yield due to 
insufficient oxidation to 12. The amide singlet is shifted to 14 ppm in the 1H-NMR spectrum of 12, consistent 
with strong hydrogen bonding to the N-oxide (amide-NH at ≈ 9.3 ppm in compounds 10, 11 and 13), a trait 
observed for related N-oxides, including diacetamide 8.4 The use of HFIP as reaction solvent enabled the 
solvation of hydrogen-bonding acceptors, including 10 and/or intermediates.15 Treating 12 with 
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methanesulfonic acid (MsOH) gave the imidazo[4,5-f]benzimidazole 14 in 42%,3,16  and benzimidazole-anilide 




Scheme 4.  Reactions of anilide derivatives of 6. 
 
The formation of 12 highlights the difference in mechanism for oxidative cyclization of 2-
(cycloamino)anilines and 2-(cycloamino)anilides (Scheme 4). Literature advocates a nitroso intermediate for 
the formation of benzimidazoles from 2-(cycloamino)anilines,9,17-19 although the o-nitroso-tert-aniline has 
never been isolated. Most recently, we observed the 4-(2-nitrosophenyl)morpholine intermediate by GC-MS 
from the oxidative cyclization to the ring-fused benzimidazole, which under certain conditions underwent 
displacement of oxazine to give 1,4,6,9-tetramethoxyphenazine.9 Evidence for the o-nitroso-tert-aniline 
intermediate 16 is now provided from the reaction of 2-(morpholin-4-yl)aniline (15) with Oxone in a 
CH2Cl2:H2O mixture (Scheme 5). Quenching this reaction at short times of 30 s and 2 min gave mostly 4-(2-
nitrophenyl)morpholine (18), which indicates formation of intermediate 16 and advantageous air-oxidation. 
After 18 and 40 h, it is apparent from the 1H NMR spectra that the morpholine signals at 3.06 and 3.85 ppm 
for 4-(2-nitrophenyl)morpholine (18) have been replaced by those for benzimidazole 17 at 4.20 and 5.05 ppm. 
The above mechanistic work clarified the requirement for diacetamides 21 and 24 for the respective 
formation of imidazobenzimidazoles 4 and 5, negating direct oxidative cyclizations from phenylenediamines 
20 and 23 (Scheme 6). Moreover treatment of diamines 20 and 23 with Oxone in HFIP under the conditions of 
Scheme 4 gave an intractable mixture. Syntheses began by nucleophilic aromatic substitution (SNAr) onto 1,5-
difluoro-2,4-dinitrobenzene and 1,4-difluoro-2,5-dinitrobenzene with bis(2-oxa-7-azaspiro[3.5]nonan-7-ium) 
ethanedioate (oxalate salt of 1), followed by SNAr with the stronger nucleophile, piperidine to give the 
respective unsymmetrically substituted dinitrobenzenes 19 and 22 in 85 and 79% yield. Hydrogenation to the 
phenylenediamines 20 and 23 occurred in 91 and 88% yield, and reaction with acetic anhydride gave the 
cyclization precursors 21 and 24 in 84 and 86% yield respectively. Oxidative cyclizations of 21 and 24 with 
Oxone (6 equiv) in acetic acid gave imidazo[4,5-f]benzimidazole 4 and imidazo[5,4-f]benzimidazole 5 in 55 and 
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Conclusions 
 
This article demonstrates the necessity for converting 4,6-di(cycloamino)-1,3-phenylenediamines to 
dianilide/diacetamide prior to imidazobenzimidazole formation. New evidence is presented for nitroso and N-
oxide intermediates in the respective oxidative cyclizations of 2-(cycloamino)anilines and 2-
(cycloamino)anilides. Oxetane is incorporated into ring-fused imidazobenzimidazoles for the first time, with 
Oxone in acetic acid allowing the formation of both [4,5-f] and [5,4-f] isomers. Future work should complete 










Materials. Pd-C (Sigma Aldrich, 5% wt. loading), EtOAc (VWR, 99.9%), pet. ether (Fisher Scientific, 40-60°C, 
Extra Pure, SLR), pivaloyl chloride (Sigma Aldrich, 99%), Oxone (Sigma Aldrich, KHSO5•0.5KHSO4•0.5K2SO4), 
HFIP (Fluorochem, 99%), NaHCO3 (Fisher Scientific, ≥99.7%), 1,5-difluoro-2,4-dinitrobenzene (Sigma Aldrich, 
t = 2 min 
t = 18 h 
t = 40 h 
t = 30 sec 
4-(2-nitrophenyl)morpholine (18) 
t = 0 
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97%), MeCN (Fisher Scientific, HPLC grade), piperidine (ACROS OrganicsTM, 99%), AcOH (Fisher Scientific, 
glacial), Ac2O (ACROS Organics
TM, 99+%), MsOH (Fluorochem, >98%), Na2CO3 (Fisher Scientific, 99.5%), D2O 
(Fluorochem, >99.9%), and MgSO4 (Fisher Scientific, Extra Pure, SLR, Dried) were used as received. CH2Cl2 
(Fisher Scientific, 99.8%) was distilled over CaH2 (ACROS Organics
TM, ca. 93%, extra pure, 0-2 mm grain size) 
prior to use. 1,1’-(4,6-Dinitro-1,3-phenylene)dipiperidine was prepared (1.198 g, 92%) by modifying the 
reported procedure,2 by reacting piperidine (2.50 mL, 29.00 mmol) and NaHCO3 (1.600 g, 19.50 mmol) with 
1,5-difluoro-2,4-dinitrobenzene (0.800 g, 3.90 mmol) in THF (30 mL) at room temperature for 1 h. The 
synthesis of 4-(2-nitrophenyl)morpholine (18) (1.042 g, 83%) was achieved by SNAr of morpholine (1.56 ml, 
18.09 mmol, Alfa Aesar, 99%) onto 1-fluoro-2-nitrobenzene (0.850 g, 6.03 mmol, Fluorochem, 99%) in the 
absence of solvent at 110 °C for 1 h. 2-(Morpholin-4-yl)aniline (15)13 was obtained in 91% yield, through 
reduction of 18 with iron powder, according to our previously reported method.9,10,12,14 The Aldabbagh group 
has previously described the synthesis of bis(2-oxa-7-azaspiro[3.5]nonan-7-ium) ethanedioate (oxalate salt of 
1),10 and  1,4-difluoro-2,5-dinitrobenzene.4 All reactions (apart from those using aqueous solutions) were 
carried out under an inert nitrogen atmosphere. Thin Layer Chromatography (TLC) was carried out on TLC 
silica gel 60 F254 plates, and preparative TLC was done on TLC Silica Gel 60 F254 glass plates. Flash column 




Scheme 6. Synthesis of (a) imidazo[4,5-f]benzimidazole 4 and (b) imidazo[5,4-f]benzimidazole 5: (i) 1 oxalate 
salt, NaHCO3, MeCN (aq), rt, 16 h; piperidine, rt, 1 h; (ii) H2 (balloon), Pd-C, EtOAc, rt, 18 h; (iii) Ac2O (10 equiv), 
AcOH, 80 °C, 30 min; (iv) Oxone (6 equiv), AcOH, 40 °C, 7 h. 
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Instruments. Melting points were measured on a Stuart Scientific melting point apparatus SMP1. IR spectra 
were recorded using a PerkinElmer Spec 1 with ATR attached. NMR spectra were recorded using a Bruker 
Avance II 400 MHz spectrometer. Chemical shifts are in ppm, relative to Me4Si. 
1H NMR NH amide and amine 
assignments were verified by D2O exchange experiments. 
13C NMR spectra are at 100 MHz with complete 
proton decoupling and assignments supported by Distortionless Enhancement by Polarization Transfer (DEPT). 
NMR assignments for synthetic targets 4 and 5 used data of reported spirocyclic oxetane ring-fused 
compounds.9,10 HRMS spectra of compounds 4, 5, 19, 21, 22 and 24 were obtained at the National University 
of Ireland Galway, using an ESI time-of-flight mass spectrometer (TOFMS) on a Waters LCT Mass Spectrometry 
instrument. HRMS spectra of all other compounds were obtained at the National Mass Spectrometry Facility 
at Swansea University using a Waters Xevo G2-S mass spectrometer with an Atmospheric Solids Analysis Probe 
(ASAP) or Thermo Scientific LTQ Orbitrap XL instrument with Nanospray Ionization (NSI). The precision of all 
accurate mass measurements was better than 5 ppm. 
Synthesis of 4,6-di(piperidin-1-yl)benzene-1,3-diamine (6). 1,1’-(4,6-Dinitro-1,3-phenylene)dipiperidine 
(0.750 g, 2.25 mmol), and Pd-C (75 mg) in EtOAc (50 mL) were stirred under H2 at room temperature for 24 h. 
The mixture was filtered through Celite and evaporated to dryness. The residue was purified by column 
chromatography using gradient elution of pet. ether and EtOAc to give the title compound (0.512 g, 83%) as a 
brown solid; Rf 0.32 (2:1 pet. ether:EtOAc); mp 172-174 °C; νmax (neat, cm
-1) 3378, 3264, 2946, 2923, 2844, 
2799, 2742, 1626, 1518, 1466, 1441, 1382, 1339, 1296, 1273, 1257, 1242, 1214, 1201, 1149, 1129, 1111, 1037, 
1029; 1H NMR (400 MHz, CDCl3) δ: 6.69 (s, 1H), 6.11 (s, 1H), 4.00-3.31 (br.s, 4H, NH2), 2.85-2.55 (br.s, 8H), 
1.64-1.55 (m, 8H), 1.54-1.36 (br.s, 4H); 13C NMR (100 MHz, CDCl3) δ: 138.6, 132.5 (both C), 112.6, 102.1 (both 
CH), 53.6, 27.1, 24.4 (all CH2); HRMS (ASAP) m/z [M+H]
+ found 275.2234, C16H27N4 requires 275.2236. 
Anilide formation. Pivaloyl chloride (45 µL, 0.37 mmol) in CH2Cl2 (8 mL) was added via syringe pump at a rate 
of 2 mL/h to diamine 6 (0.103 g, 0.37 mmol) in CH2Cl2 (8 mL). The mixture was stirred for a further 2 h at room 
temperature. H2O (20 mL) was added, and the mixture was extracted with CH2Cl2 (2 x 20 mL). The combined 
organic extracts were dried (MgSO4), evaporated and purified by column chromatography using gradient 
elution of pet. ether and EtOAc. 
N-[5-Amino-2,4-di(piperidin-1-yl)phenyl]-2,2-dimethylpropanamide (10). (81 mg, 61%); pale brown solid; Rf 
0.44 (7:3 pet. ether:EtOAc); mp 149-151 °C; νmax (neat, cm
-1) 3423, 3333, 2931, 2851, 2801, 2739, 2360, 1669 
(C=O), 1618, 1593, 1519, 1480, 1435, 1377, 1364, 1321, 1272, 1235, 1206, 1193, 1150, 1121, 1110, 1063, 
1035, 1029; 1H NMR (400 MHz, CDCl3) δ: 9.13 (s, 1H, NH), 7.92 (s, 1H), 6.85 (s, 1H), 4.05-3.82 (br.s, 2H, NH2), 
2.90-2.62 (m, 8H), 1.75-1.64 (m, 8H), 1.63-1.47 (br.s, 4H), 1.31 (s, 9H, Me); 13C NMR (100 MHz, CDCl3) δ: 176.2 
(C=O), 138.9, 135.7, 133.8, 130.5 (all C), 112.4, 105.5 (both CH), 54.3, 53.0 (both CH2), 40.0 (C), 27.8 (Me), 27.3, 
26.9, 24.4, 24.1 (all CH2); HRMS (ASAP) m/z [M+H]
+ found 359.2809, C21H35N4O requires 359.2811. 
N,N'-[4,6-Di(piperidin-1-yl)-1,3-phenylene]bis(2,2-dimethylpropanamide) (11). (22 mg, 14%); brown solid; Rf 
0.37 (pet. ether:EtOAc); mp 236-237 °C; νmax (neat, cm
-1) 3344, 2949, 2930, 2917, 2849, 1682 (C=O), 1596, 
1519, 1480, 1448, 1428, 1393, 1377, 1362, 1356, 1340, 1309, 1269, 1219, 1190, 1162, 1150, 1103, 1063, 1027; 
1H NMR (400 MHz, CDCl3) δ: 9.36 (s, 1H), 8.77 (s, 1H, NH), 6.95 (s, 1H), 2.74 (t, J 5.2 Hz, 8H), 1.75-1.68 (m, 8H), 
1.62-1.55 (m, 4H), 1.30 (s, 18H, Me); 13C NMR (100 MHz, CDCl3) δ: 175.6 (C=O), 138.0, 130.8 (both C), 112.4, 
110.7 (both CH), 53.9 (CH2), 39.9 (C), 27.8 (Me), 27.1, 24.1 (CH2); HRMS (ASAP) m/z [M+H]
+ found 443.3384, 
C26H43N4O2 requires 443.3386. 
Reaction of amine-anilide 10 with Oxone (in the absence of acid). Oxone (0.277 g, 0.90 mmol) was added to 
amine-anilide 10 (65 mg, 0.18 mmol) in HFIP (3.6 mL, 10% aq.) and stirred at room temperature for 16 h. H2O 
(10 mL) was added, and the mixture extracted with CH2Cl2 (2 x 10 mL). The organic extracts were dried 
(MgSO4), evaporated and purified by column chromatography using gradient elution of CH2Cl2 and MeOH. 
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2,2-Dimethyl-N-[8-(1-oxidopiperidin-1-yl)-1,2,3,4-tetrahydropyrido[1,2-a]benzimidazol-7-yl]propenamide 
(12). (39 mg, 58%); pale brown solid; Rf 0.26 (9:1 CH2Cl2:MeOH); mp (decomp. >161 °C); νmax (neat, cm
-1) 2952, 
2927, 2866, 1652 (C=O), 1594, 1497, 1474, 1430, 1417, 1366, 1327, 1273, 1199, 1148, 1011; 1H NMR (400 
MHz, CDCl3) δ: 13.99 (s, 1H, NH), 8.84 (s, 1H), 7.29 (s, 1H), 4.05 (t, J 6.0 Hz, 2H), 3.84 (d, J 10.7 Hz, 2H), 3.59-
3.47 (m, 2H), 3.08 (t, J 6.3 Hz, 2H), 2.80-2.70 (m, 2H), 2.17-2.11 (m, 2H), 2.05-2.01 (m, 2H), 1.89 (d, J 13.0 Hz, 
1H), 1.75 (d, J 13.6 Hz, 2H), 1.48-1.37 (m, 1H), 1.35 (s, 9H, Me); 13C NMR (100 MHz, CDCl3) δ: 176.9 (C=O), 
154.1, 142.7, 137.6, 130.6, 129.1 (all C), 114.0, 98.2 (both CH), 66.5, 42.5 (both CH2), 40.0 (C), 27.8 (Me), 25.5, 
22.5, 21.9, 20.9, 20.5 (all CH2); HRMS (ASAP) m/z [M+H]
+ found 371.2447, C21H31N4O2 requires 371.2447, m/z 
372 (25%), 371 (M+1, 100%), 356 (16%), 355 (M-16, 73%), 354 (26%), 353 (M-18, 97%), 269 (M-102, 28%). 
2,2-Dimethyl-N-[8-(piperidin-1-yl)-1,2,3,4-tetrahydropyrido[1,2-a]benzimidazol-7-yl]propenamide (13). (19 
mg, 29%); brown solid; Rf 0.44 (9:1 CH2Cl2:MeOH); mp 171-173 °C; νmax (neat, cm
-1) 3340, 2935, 2863, 2809, 
1667 (C=O), 1589, 1511, 1473, 1440, 1418, 1365, 1322, 1268, 1242, 1194, 1146, 1136, 1064, 1034; 1H NMR 
(400 MHz, CDCl3) δ: 9.25 (s, 1H, NH), 8.74 (s, 1H), 7.08 (s, 1H), 4.03 (t, J 6.1 Hz, 2H), 3.05 (t, J 6.4 Hz, 2H), 2.96-
2.67 (br.s, 4H), 2.16-2.06 (m, 2H), 2.05-1.95 (m, 2H), 1.84-1.54 (m, 6H), 1.36 (s, 9H, Me); 13C{1H} NMR (100 
MHz, CDCl3) δ: 176.0 (C=O), 151.7, 139.7, 139.1, 130.2, 129.8 (all C), 109.0, 101.0 (both CH), 54.7, 42.4 (both 
CH2), 40.1 (C), 27.9 (Me), 27.2, 25.3, 24.1, 22.7, 20.7 (all CH2); HRMS (ASAP) m/z [M+H]
+ found 355.2495, 
C21H31N4O requires 355.2498. 
Ring-closure with acid. MsOH (0.05 mL, 0.77 mmol) was added to a solution of N-oxide 12 (28 mg, 0.08 mmol) 
in CH2Cl2 (0.8 mL) and stirred at room temperature for 5 h. Na2CO3 (satd., 2 mL) was added, and the mixture 
extracted with CH2Cl2 (3 x 2 mL). The organic extracts were dried (MgSO4), evaporated and purified by 
preparative TLC.  
2,2-Dimethyl-N-[8-(piperidin-1-yl)-1,2,3,4-tetrahydropyrido[1,2-a]benzimidazol-7-yl]propenamide (13). (12 
mg, 44%); Rf 0.44 (9:1 CH2Cl2:MeOH); spectral data and melting point consistent with the above.  
1,2,3,4,8,9,10,11-Octahydropyrido[1,2-a]pyrido[1’,2’:1,2]imidazo[4,5-f]benzimidazole (14).3,16 (8 mg, 42%); 
off-white solid; Rf 0.20 (9:1 CH2Cl2:MeOH); mp (decomp. >261 °C; lit. m.p.
3 decomp. 266-270 °C); 1H NMR (400 
MHz, CDCl3) δ: 7.95 (d, J 0.8 Hz, 1H), 7.04 (d, J 0.8 Hz, 1H), 4.09 (t, J 6.1 Hz, 4H), 3.11 (t, J 6.4 Hz, 4H), 2.20-2.13 
(m, 4H), 2.07-2.00 (m, 4H). 
Reaction of aniline 15 with Oxone. Aniline 15 (0.356 g, 2.00 mmol) and Oxone (1.846 g, 6.01 mmol) in CH2Cl2 
(4 mL) and H2O (1 mL) were rapidly stirred at rt. Aliquots (0.2 mL) were taken at the times shown in Scheme 5, 
quenched with water (0.5 mL), and extracted with CDCl3 (0.5 mL) for 
1H NMR analysis. After 2 min, 
nitrobenzene 18 was the apparent major product; 1H NMR (400 MHz, CDCl3) δ: 7.78 (dd, J 8.1 Hz, 1.6 Hz, 1H), 
7.53-7.48 (m, 1H), 7.16 (dd, J 8.3, 1.2 Hz, 1H), 7.11-7.06 (m, 1H), 3.85 (t, J 4.6 Hz, 4H), 3.06 (t, J 4.6 Hz, 4H). The 
reaction under the same conditions was stirred for 40 h. H2O (5 mL) was added, and the mixture extracted 
with CH2Cl2 (2 x 6 mL). The organic extracts were dried (MgSO4), evaporated and purified by column 
chromatography using gradient elution of pet. ether and EtOAc to give 3,4-dihydro-1H-[1,4]oxazino[4,3-
a]benzimidazole (17) (0.259 g, 74%) as a pale brown solid; Rf 0.21 (EtOAc); mp 123-125 °C (lit m.p.
17 129-130 
°C); 1H NMR (400 MHz, CDCl3) δ: 7.76-7.72 (m, 1H), 7.37-7.32 (m, 1H), 7.31-7.27 (m, 2H), 5.05 (s, 2H), 4.24-4.16 
(m, 4H). Spectral data and melting point were consistent with reported.20  
Procedure for the synthesis of nitrobenzenes 19 and 22. Oxalate salt of 1 (0.540 g, 1.57 mmol), NaHCO3 
(1.020 g, 12.48 mmol) and 1,5-difluoro-2,4-dinitrobenzene or 1,4-difluoro-2,5-dinitrobenzene (0.636 g, 3.12 
mmol) in MeCN (40 ml) and H2O (4 ml) were stirred at room temperature for 16 h. Piperidine (3.00 ml, 30.42 
mmol) was added to the mixture and stirred for a further 1 h. The mixture was evaporated, EtOAc (50 mL) 
added, washed with brine (3 x 50 mL), dried (MgSO4), and evaporated to dryness. The residue was purified by 
column chromatography using gradient elution of pet. ether and EtOAc.  
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1-(2,4-Dinitro-5-piperidin-1-ylphenyl)-2-oxa-7-azaspiro[3.5]nonane (19). (0.993 g, 85%); yellow solid; Rf 0.32 
(1:1 pet. Ether:EtOAc); mp 156-157 °C; νmax (neat, cm
-1) 2941, 2855, 1600, 1555, 1489 (NO2), 1441, 1326 (NO2), 
1299, 1254; 1H NMR (400 MHz, CDCl3) δ: 8.66 (s, 1H), 6.25 (s, 1H), 4.48 (s, 4H, OCH2), 3.12 (t, J 5.3 Hz, 4H), 3.04 
(t, J 5.5 Hz, 4H), 2.06 (t, J 5.5 Hz, 4H), 1.76-1.69 (m, 4H), 1.69-1.62 (m, 2H); 13C NMR (100 MHz, CDCl3) δ: 150.8, 
131.1, 130.6 (all C), 130.0, 107.4 (both CH), 81.4 (OCH2), 52.3, 48.6 (both CH2), 38.5 (C), 34.4, 25.5, 23.9 (all 
CH2); HRMS (ESI) m/z [M+H]
+ found 377.1813, C18H25N4O5 requires 377.1825. 
1-(2,5-Dinitro-4-piperidin-1-ylphenyl)-2-oxa-7-azaspiro[3.5]nonane (22). (0.926 g, 79%); red-brown solid; Rf 
0.49 (4:1 pet. Ether:EtOAc); mp 148-149 °C; νmax (neat, cm
-1) 2929, 2859, 2810, 1533, 1495 (NO2), 1466, 1445, 
1410, 1385, 1346 (NO2), 1324 (NO2), 1272, 1236, 1225, 1209, 1131, 1042; 
1H NMR (400 MHz, CDCl3) δ: 7.45 (s, 
1H), 7.41 (s, 1H), 4.45 (s, 4H, OCH2), 2.95 (t, J 5.3 Hz, 4H), 2.87 (t, J 5.5 Hz, 4H), 1.99 (t, J 5.5 Hz, 4H), 1.71-1.65 
(m, 4H), 1.60-1.53 (m, 2H); 13C NMR (100 MHz, CDCl3) δ: 146.8, 144.9, 141.8, 139.5 (all C), 119.3, 118.1 (both 
CH), 81.6 (OCH2), 53.1, 49.8 (both CH2), 38.2 (C), 34.9, 25.9, 23.8 (all CH2); HRMS (ESI) m/z [M+H]
+ found 
377.1818, C18H25N4O5 requires 377.1825. 
Procedure for the synthesis of diamines 20 and 23. Dinitrobenzene 19 or 22 (0.500 g, 1.33 mmol), and Pd-C 
(50 mg) in EtOAc (50 mL) were stirred under H2 (balloon) at room temperature for 16 h. The mixture was 
filtered through Celite and evaporated to dryness. 
4-(2-Oxa-7-azaspiro[3.5]nonan-7-yl)-6-(piperidin-1-yl)benzene-1,3-diamine (20). (0.381 g, 91%); brown solid; 
mp 187-188 °C; νmax (neat, cm
-1) 3372, 3264, 2951, 2920, 2848, 2740, 1626, 1519, 1468, 1442, 1380, 1296, 
1278, 1257, 1246, 1215, 1149, 1132, 1113, 1036, 1026; 1H NMR (400 MHz, CDCl3) δ: 6.60 (s, 1H), 6.07 (s, 1H), 
4.40 (s, 4H, OCH2), 3.78-3.64 (br.s, 4H, NH2), 2.81-2.41 (br.s, 8H), 2.02-1.79 (br.s, 4H), 1.64-1.53 (m, 4H), 1.52-
1.36 (br.s, 2H); 13C NMR (100 MHz, CDCl3) δ: 138.9, 138.5, 132.5, 131.2 (all C), 112.4, 102.1 (both CH), 82.1 
(OCH2), 53.6, 49.6 (both CH2), 38.5 (C), 36.1, 27.1, 24.4 (all CH2); HRMS (NSI) m/z [M+H]
+ found 317.2342, 
C18H29N4O1 requires 317.2336. 
2-(2-Oxa-7-azaspiro[3.5]nonan-7-yl)-5-(piperidin-1-yl)benzene-1,4-diamine (23). (0.369 g, 88%); grey solid; 
mp 197-199 °C; νmax (neat, cm
-1) 3386, 3302, 3273, 3162, 2924, 2855, 2800, 2739, 1585, 1511, 1462, 1450, 
1432, 1342, 1301, 1246, 1200, 1111, 1033; 1H NMR (400 MHz, CDCl3) δ: 6.40 (s, 1H), 6.35 (s, 1H), 4.40 (s, 4H, 
OCH2), 3.64-3.40 (br.s, 4H, NH2), 2.78-2.54 (m, 8H), 1.96-1.84 (br.s, 4H), 1.65-1.56 (m, 4H), 1.53-1.40 (br.s, 2H); 
13C{1H} NMR (100 MHz, CDCl3) δ: 137.7, 136.1, 133.5, 133.3 (all C), 108.1, 107.8 (both CH), 82.0 (OCH2), 53.0, 
49.0 (both CH2), 38.5 (C), 35.9, 26.9, 24.4 (all CH2); HRMS (NSI) m/z [M+H]
+ found 317.2339, C18H29N4O1 
requires 317.2336. 
Procedure for the synthesis of diacetamides 21 and 24. Diamine 20 or 23 (0.354 g, 1.12 mmol) in Ac2O (1.06 
mL, 11.20 mmol) and AcOH (30 mL) was stirred at 80 °C for 30 min. The mixture was evaporated, NaHCO3 (5%, 
100 mL) added and stirred for 1 h. The precipitate was collected, washed with water, dried, and recrystallized 
from EtOAc. 
N,N’-[4-(2-Oxa-7-azaspiro[3.5]nonan-7-yl)-6-piperidin-1-yl-1,3-phenylene]diacetamide (21). (0.375 g, 84%); 
white solid; mp 226-228 °C; νmax (neat, cm
-1) 3291, 2935, 2856, 2797, 2735, 1728, 1672 (C=O), 1659, 1589, 
1524, 1491, 1420, 1378, 1368, 1289, 1276, 1256, 1232, 1218, 1196, 1158, 1136, 1122, 1112, 1066, 1032; 1H 
NMR (400 MHz, CDCl3) δ: 8.98 (s, 1H), 8.19 (s, 1H, NH), 8.07 (s, 1H, NH), 6.76 (s, 1H), 4.43 (s, 4H, OCH2), 2.71-
2.58 (m, 8H), 2.13-2.06 (m, 6H, Me), 2.00-1.90 (br.s, 4H), 1.68-1.60 (m, 4H), 1.55-1.46 (br.s, 2H); 13C NMR (100 
MHz, CDCl3) δ: 167.5 (C=O), 138.6, 137.4, 130.3, 129.8 (all C), 112.0 (2 x CH), 81.7 (OCH2), 53.8, 49.9 (both 
CH2), 38.3 (C), 35.8, 26.9 (both CH2), 24.8 (Me), 24.0 (CH2); HRMS (ESI) m/z [M-H]
- found 399.2397, C22H31N4O3 
requires 399.2396. 
N,N’-[2-(2-Oxa-7-azaspiro[3.5]nonan-7-yl)-5-(piperidin-1-yl)-1,4-phenylene]diacetamide (24). (0.386 g, 86%); 
pale brown solid; mp 221-222 °C; νmax (neat, cm
-1) 3362, 3286, 2941, 2869, 2808, 1672 (C=O), 1527, 1477, 
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1417, 1367, 1296, 1239, 1220, 1195, 1108, 1062; 1H NMR (400 MHz, CDCl3) δ: 8.44 (s, 1H, NH), 8.33 (s, 1H, 
NH), 8.16 (s, 1H), 8.11 (s, 1H), 4.42 (s, 4H, OCH2), 2.71 (t, J 5.1 Hz, 4H), 2.66 (t, J 5.1 Hz, 4H), 2.11 (s, 3H, Me), 
2.10 (s, 3H, Me), 2.01-1.87 (br.s, 4H), 1.68-1.59 (m, 4H), 1.57-1.46 (br.s, 2H); 13C NMR (100 MHz, CDCl3) δ: 
168.0, 167.9 (both C=O), 139.3, 137.7, 129.4, 129.3 (all C), 112.0, 111.6 (both CH), 81.7 (OCH2), 53.7, 49.9 
(both CH2), 38.3 (C), 35.9, 27.0 (both CH2), 24.9 (Me), 24.0 (CH2); HRMS (ESI) m/z [M+H]
+ found 401.2536, 
C22H33N4O3 requires 401.2553. 
Procedure for the synthesis of imidazobenzimidazoles 4 and 5. Diacetamide 21 or 24 (50 mg, 0.13 mmol) and 
Oxone (0.250 g, 0.81 mmol) in AcOH (5 mL) were stirred at 40 °C for 7 h. The mixture was evaporated, H2O (10 
mL) added, neutralized with solid Na2CO3, and extracted with CH2Cl2 (3 x 5 mL). The organic extracts were 
dried (MgSO4), evaporated and recrystallized from EtOAc. 
6,7,11,12,13,14-Hexahydro-1H-2-oxa-7-azaspiro[3.5]nonan[1,2-a]pyrido[1’,2’:1,2]imidazo[4,5-f]benz- 
imidazole (4). (22 mg, 55%); brown solid; mp (decomp. >279 °C); νmax (neat, cm
-1) 3386, 2946, 2892, 1661, 
1526, 1484, 1432, 1420, 1369, 1312, 1254, 1196, 1159, 1136, 1098; 1H NMR (400 MHz, CDCl3) δ: 7.90 (d, J 0.9 
Hz, 1H, 16-H), 6.99 (d, J 0.9 Hz, 1H, 9-H), 4.54 (s, 4H, 3,5-CH2), 4.08 (t, J 6.3 Hz, 2H, 7-CH2), 4.03 (t, J 6.1 Hz, 2H, 
11-CH2), 3.34 (s, 2H, 1-CH2), 3.05 (t, J 6.4 Hz, 2H), 2.43 (t, J 6.3 Hz, 2H), 2.14-2.06 (m, 2H), 2.01-1.94 (m, 2H); 
13C 
NMR (100 MHz, CDCl3) δ: 152.1, 149.5, 140.1, 140.0, 132.2, 131.6 (all C), 107.6 (16-CH), 87.3 (9-CH), 80.7 (3,5-
CH2), 42.6, 38.9 (7,11-CH2), 38.0 (C), 35.0 (1-CH2), 30.8, 25.7, 22.7, 20.8 (all CH2); HRMS (ESI) m/z [M+H]
+ found 
309.1720, C18H21N4O requires 309.1715. 
6,7,11,12,13,14-Hexahydro-1H-2-oxa-7-azaspiro[3.5]nonan[1,2-a]pyrido[1’,2’:1,2]imidazo[5,4-f]benzimid- 
azole (5). (20 mg, 49%); orange solid; mp (decomp. >297 °C); νmax (neat, cm
-1) 2926, 2856, 1533, 1488, 1449, 
1418, 1362, 1279, 1240, 1192, 1166, 1135, 1093; 1H NMR (400 MHz, CDCl3) δ: 7.53 (d, J 0.8 Hz, 1H), 7.52 (d, J 
0.8 Hz, 1H), 4.64 (ABq, J 6.2 Hz, 4H, 3,5-CH2), 4.21 (t, J 6.3 Hz, 2H, 7-CH2), 4.16 (t, J 6.1 Hz, 2H, 14-CH2), 3.44 (s, 
2H, 1-CH2), 3.14 (t, J 6.4 Hz, 2H), 2.52 (t, J 6.3 Hz, 2H), 2.24-2.17 (m, 2H), 2.10-2.04 (m, 2H); 
13C NMR (100 MHz, 
CDCl3), 152.6, 150.0, 139.90, 139.85, 132.5, 132.0 (all C), 97.2, 97.0 (both CH), 80.8 (3,5-CH2), 42.6, 38.9 (7,14-
CH2), 38.0 (C), 35.2 (1-CH2), 30.8, 25.7, 22.7, 20.8 (all CH2); HRMS (ESI) m/z [M+H]
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1H and 13C NMR spectra of novel compounds 4-6, 10-13, and 19-24, and 1H NMR spectra of known compounds 
14, 17 and 18 can be found in the Supplementary Material file. For spirocyclic oxetane ring-fused compounds 
4 and 5 atom numbering is included, which is derived from the systematic compound names.  
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